Alimera Sciences, Inc. (ALIM) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
6310 Town Square
Alpharetta, GA 30005
United States of America (the)
Phone
678 990 5740
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
154
First IPO Date
November 04, 2019
| Name | Title | Pay | Year Born |
| Richard S. Eiswirth Jr. | Chief Executive Officer & Director | 949,272 | 1968 |
| Jason Werner | Chief Operating Officer | 225,659 | 1978 |
| David R. Holland | Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications & Managed Markets | 413,500 | 1964 |
| Philip Ashman | President of International Operations | 516,981 | 1965 |
| Elliot Maltz | Chief Financial Officer & Treasurer | 0 | 1985 |
| David Dyer | Chief Retina Specialist | 0 | N/A |
| Todd Michael Wood | President of U.S. Operations | 0 | 1969 |
| Christopher S. Visick | Vice President, General Counsel & Secretary | 0 | N/A |
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.